SCHEMBL20943428

SCHEMBL20943428

C=C(CCCCC)C(O)C(C)C(=O)C1C(=O)OC[C@@H]1C(C)C

nearest known ligand 0.55

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
IL6ST P40189 6/20 0.55
STAT3 P40763 1/20 0.55
NAAA Q02083 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20943427 1.00 IL6ST (0.55) IL6STSTAT3NAAA
SCHEMBL22261830 0.71 IL6ST (1.00) IL6STSTAT3NAAA
SCHEMBL22261831 0.71 IL6ST (1.00) IL6STSTAT3NAAA
SCHEMBL23926079 0.61 CES2 (0.40)
SCHEMBL10903055 0.56 AKR1B1 (0.48)
SCHEMBL10594885 0.56 AKR1B1 (0.48)
SCHEMBL14091098 0.56
SCHEMBL19057211 0.56 CES2 (0.42)
SCHEMBL31519438 0.56 IL6ST (0.65) IL6STSTAT3NAAA
SCHEMBL25110725 0.55 CES2 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3700514-B1 COMBINATION OF IL-8 INHIBITORS AND IL-6/GP-130 INHIBITORS FOR USE IN THE TREATMENT OF LUNG METASTASIS ASSOCIATED TO OSTEOSARCOMA DOMPE FARM SPA (IT) 2025-03-19 EP claimed
EP-4548916-A1 IL-8 INHIBITORS FOR USE IN THE TREATMENT OF SOME SARCOMAS Dompé farmaceutici SpA (IT) 2025-05-07 EP disclosed
EP-3700514-B1 COMBINATION OF IL-8 INHIBITORS AND IL-6/GP-130 INHIBITORS FOR USE IN THE TREATMENT OF LUNG METASTASIS ASSOCIATED TO OSTEOSARCOMA DOMPE FARM SPA (IT) 2025-03-19 EP disclosed
US-11660291-B2 IL-8 inhibitors for use in the treatment of some sarcomas DOMPE' FARMACEUTICI S.P.A. (IT) 2023-05-30 US disclosed
US-20210361627-A1 IL-8 INHIBITORS FOR USE IN THE TREATMENT OF SOME SARCOMAS DOMPE' FARMACEUTICI (IT) 2021-11-25 US disclosed
EP-3700514-A1 IL-8 INHIBITORS FOR USE IN THE TREATMENT OF SOME SARCOMAS Dompé farmaceutici S.p.A. (IT) 2020-09-02 EP disclosed
EP-3476390-A1 IL-8 INHIBITORS FOR USE IN THE TREATMENT OF SARCOMAS Dompé farmaceutici S.p.A. (IT) 2019-05-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210361627-A1 IL-8 INHIBITORS FOR USE IN THE TREATMENT OF SOME SARCOMAS CXCL8, CXCR1, CXCR2 IL6ST 25/4885STAT3 173/4885NAAA 4287/4885
US-11660291-B2 IL-8 inhibitors for use in the treatment of some sarcomas CXCL8, CXCR1, CXCR2 IL6ST 25/4885STAT3 173/4885NAAA 4287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.